Aligos Financial Statements From 2010 to 2024
| ALGS Stock | USD 25.72 0.21 0.82% |
Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.
Aligos |
Aligos Therapeutics Company Shares Outstanding Analysis
Aligos Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Aligos Therapeutics Shares Outstanding | 3.46 M |
Most of Aligos Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aligos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Aligos Therapeutics has 3.46 M of shares currently outstending. This is 98.08% lower than that of the Biotechnology sector and 96.76% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.39% higher than that of the company.
Aligos Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aligos Therapeutics's current stock value. Our valuation model uses many indicators to compare Aligos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aligos Therapeutics competition to find correlations between indicators driving Aligos Therapeutics's intrinsic value. More Info.Aligos Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Aligos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Aligos Therapeutics Financial Statements
Aligos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.